Imatinib mesylate (Gleevec®) enhances mature osteoclast apoptosis and suppresses osteoclast bone resorbing activity-Reference-Cited by-同舟云学术

Imatinib mesylate (Gleevec®) enhances mature osteoclast apoptosis and suppresses osteoclast bone resorbing activity

Published:2006-12 Issue:1-3 Volume:551 Page:27-33
ISSN:0014-2999
Container-title:European Journal of Pharmacology
language:en
Short-container-title:European Journal of Pharmacology

Author:

El Hajj Dib Iman,Gallet Marlène,Mentaverri Romuald,Sévenet Nicolas,Brazier Michel,Kamel Said

Publisher

Elsevier BV

Subject

Pharmacology

Reference42 articles.

1. Regulation of osteoclast apoptosis by ubiquitylation of proapoptotic BH3-only Bcl-2 family member Bim;Akiyama;EMBO J.,2003

2. Altered bone and mineral metabolism in patients receiving imatinib mesylate;Berman;N. Engl. J. Med.,2006

3. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors;Buchdunger;J. Pharmacol. Exp. Ther.,2000

4. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins;Carroll;Blood,1997

5. M-CSF neutralization and egr-1 deficiency prevent ovariectomy-induced bone loss;Cenci;J. Clin. Invest.,2000

Cited by 57 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CSF1R as a Therapeutic Target in Bone Diseases: Obvious but Not so Simple;Current Osteoporosis Reports;2022-10-05

2. 1,3,5-triazines inhibit osteosarcoma and avert lung metastasis in a patient-derived orthotopic xenograft mouse model with favorable pharmacokinetics;IRAN J BASIC MED SCI;2022

3. A general strategy for the synthesis of α-trifluoromethyl- and α-perfluoroalkyl-β-lactams via palladium-catalyzed carbonylation;Chemical Science;2021

4. “Take My Bone Away?” Hypoxia and bone: A narrative review;Journal of Cellular Physiology;2020-07-09

5. Synthesis of imatinib, a tyrosine kinase inhibitor, labeled with carbon-14;Journal of Labelled Compounds and Radiopharmaceuticals;2020-02-05